AGENT DCB Maintains Superiority Over Uncoated Balloon at 3 Years for In-Stent Restenosis in AGENT IDE

Join our community to access additional content!

CRT Community

$0.00

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Join Now!
Already have an account? Login Now

CRT Community Premium

$650.00 annually

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Complimentary subscription to electronic version of the CRM Journal

Access to CRT Meeting Registration Discounts

CRT Premium Content, including on-demand videos and presentation downloads

Join Now!
Already have an account? Login Now
News

AGENT DCB Maintains Superiority Over Uncoated Balloon at 3 Years for In-Stent Restenosis in AGENT IDE

Posted: 03/07/2026
Author:
Nathan Gray, CRTonline.org
News Articles Conference News Plain Old Balloon Angioplasty Endovascular 2026 Late-Breaking Trials CRT DCB Peripheral Vascular Interventions Coronary Coronary Interventions

Treatment with the AGENT paclitaxel-coated balloon sustained its superiority over conventional balloon angioplasty (BA) for the reduction of target lesion failure (TLF) at three years in patients with coronary in-stent restenosis (ISR), according to new follow-up data from the AGENT IDE trial.

Most Viewed Pages

DMV (July 2026) Feasibility and Challenges of the UNICORN Technique in Native Aortic Valve TAVI

Increased Risks Associated With Longer Periods Between AF Diagnoses and Ablation, Registry Analysis Finds

RDN Lowers Blood Pressure, But Doesn’t Reduce Risk of Heart Attack, Stroke in Patients With Hypertension

King and I | S7 E1 | Politics of Federal Funding Cuts

Older, Symptomatic Patients With Mild Hypertrophic Cardiomyopathy More Likely to Develop MACE: SHaRe Registry

Invalid Configuration Data. Please look into Pipeline and other configurations.

No record found for the searched term.

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Join our community to access additional content!

CRT Community

CRT Community Premium

News

AGENT DCB Maintains Superiority Over Uncoated Balloon at 3 Years for In-Stent Restenosis in AGENT IDE

Most Viewed Pages

Explore the Site

Stay Connected